Eloxx Pharmaceuticals, Inc. (ELOX) Form 424B3 — Oct 21, 2026
Eloxx Pharmaceuticals filed Prospectus Supplement No. 1 to register resale of 600,000 shares plus up to 4,358,919 shares issuable on pre-funded warrants held by Domicilium and Coastlands selling stockholders from prior private placements, with warrants exercisable at $0.11 versus a $12.50 market price on October 19, 2026. The underlying 8-K also discloses that the board expanded from five to six directors and appointed Geno J. Germano, a 35-year pharma veteran and former Pfizer Group President who previously led a $14 billion global innovative pharma business, with an option grant for 13,587 shares at $12.50.
Key figures
- Shares Offered
- 600000
- Topline data
- first half of 2029
- Board size after
- 6
- Board size before
- 5
- First patient dosing
- Q3 2027
- Germano option shares
- 13587
- Last sale price oct19
- 12.5
- Express trial enrollment
- approximately 60 adults
- Pre funded warrant shares
- 4358919
- Express trial duration weeks
- 52
- Germano option exercise price
- 12.5
- Pre funded warrant exercise price
- 0.11
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.